

Remarks/Arguments

Claims 1 and 3-6 are currently pending in the instant application. Claims 1 and 3-6 were rejected under 35 U.S.C. §103(a) as being obvious over Blake and Patani. Applicant is filing this request for continued examination to ensure that all art submitted in the information disclosure statement of February 9, 2011 is made of record before continuing with the appeal, a notice of which was filed March 3, 2011. Applicant reiterates all remarks made in the previous two responses and submits that the Examiner has not provided any motivation to modify the prior art compound as she has done to arrive at the instantly claimed invention. The mere fact that one could have made modifications to the prior art compound to make the instantly claimed invention or thousands of other possible compounds does not render any of such compounds obvious. Absent the identification of a specific reason to make the modifications identified by the examiner, which she has failed to provide, the instantly claimed invention is no more obvious than the thousands of other compounds which would have also been created by making similar modifications. Accordingly, Applicant respectfully submits that a *prima facie* case of obviousness has not been established that the claims stand in condition for allowance.

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
+1 862 7789587

Date: 10/3/11

Respectfully submitted,



Daniel Woods
Attorney for Applicant
Reg. No. 59,864